中国普通外科杂志2025，Vol.34Issue(2)：222-228,7.DOI:10.7659/j.issn.1005-6947.250016
肝内胆管癌新辅助及转化治疗进展与争议
Advancements and controversies in neoadjuvant and conversion therapies for intrahepatic cholangiocarcinoma
摘要
Abstract
Intrahepatic cholangiocarcinoma(ICC)typically has an insidious onset,and most patients have already progressed to advanced stages by the time of initial diagnosis,missing the opportunity for radical surgery.Surgical treatment is the main approach for ICC,but the high early recurrence rate after surgery and poor prognosis remain significant challenges.In recent years,there have been continuous breakthroughs in chemotherapy,immunotherapy,targeted therapy,and combination therapies for ICC,ushering in a new era for systemic treatment.With the improvement of treatment effects,conversion therapy,and neoadjuvant therapy have emerged as prominent topics of interest.However,with the deepening of clinical diagnosis and treatment practices,complex and unresolved issues have gradually emerged,triggering extensive discussions among scholars at home and abroad.Currently,there is no clear,standardized diagnostic and therapeutic process for conversion therapy and neoadjuvant therapy in the guidelines of the National Comprehensive Cancer Network or the Chinese Society of Clinical Oncology.This article aims to comprehensively review the latest progress in neoadjuvant and conversion therapy for ICC and deeply explore the controversial focuses therein,with the expectation of providing useful references for clinical practice and promoting the further development of this field.关键词
胆管肿瘤/胆管,肝内/肿瘤辅助疗法/转化治疗/免疫疗法/分子靶向治疗Key words
Bile Duct Neoplasms/Bile Ducts,Intrahepatic/Neoadjuvant Therapy/Conversion Therapy/Immunotherapy/Molec-ular Targeted Therapy分类
临床医学引用本文复制引用
刘红枝,曾永毅..肝内胆管癌新辅助及转化治疗进展与争议[J].中国普通外科杂志,2025,34(2):222-228,7.基金项目
国家自然科学基金资助项目(62275050) （62275050）
国家重点研发计划基金资助项目(2022YFC2407304) （2022YFC2407304）
福建省科技创新联合基金资助项目(2019Y9108) （2019Y9108）
福建省卫健委中青年科研重大基金资助项目(2021ZONZD013). （2021ZONZD013）
